Arrowhead Pharmaceuticals (NASDAQ:ARWR) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other research firms have also recently issued reports on ARWR. ValuEngine upgraded Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, October 2nd. Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 target price on the stock in a research note on Monday, November 27th. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, September 25th. William Blair upgraded Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, September 18th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $3.17.

Arrowhead Pharmaceuticals (NASDAQ ARWR) traded down $0.08 during mid-day trading on Friday, reaching $3.49. The company’s stock had a trading volume of 1,011,417 shares, compared to its average volume of 771,375. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $4.54.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. ING Groep NV bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at about $3,500,000. Geode Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 3.4% during the first quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock valued at $1,226,000 after purchasing an additional 21,654 shares in the last quarter. Allianz Asset Management GmbH bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter valued at about $1,958,000. LMR Partners LLP bought a new stake in shares of Arrowhead Pharmaceuticals during the second quarter valued at about $467,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 10.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock valued at $742,000 after purchasing an additional 16,103 shares in the last quarter. Institutional investors and hedge funds own 20.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Arrowhead Pharmaceuticals (ARWR) Rating Lowered to Hold at BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/02/arrowhead-pharmaceuticals-arwr-rating-lowered-to-hold-at-bidaskclub.html.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.